Physician profile
Christopher B Keller
NPI 1598820268
$1,405.03
in general payments reported to CMS, 2019-2025
16 companies · $225 in 2025
The $225 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $93.93 · 2020: $96.58 · 2021: $346 · 2022: $292 · 2023: $176 · 2024: $174 · 2025: $225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $536 · Education: $39.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $536.34 |
| Education | $39.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $385.79 | 2020-2025 | |
| Madrigal Pharmaceuticals | $243.32 | 2024-2025 | Rezdiffra |
| Medtronic, INC. | $131.26 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $118.42 | 2020-2025 | Xifaxan |
| Lilly USA, LLC | $107.68 | 2022 | |
| Gilead Sciences, INC. | $89.06 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $79.07 | 2019-2022 | |
| Ucb, INC. | $63.47 | 2019 | |
| Ironwood Pharmaceuticals, INC | $46.76 | 2019-2021 | |
| Braintree Laboratories, INC. | $37.56 | 2021-2022 | |
| Micro-Tech Endoscopy USA, INC. | $33.52 | 2023-2024 | Sureclip, Cold Snares |
| Genzyme Corporation | $28.80 | 2022 | |
| Capsovision, INC. | $16.89 | 2023 | Capsocam Plus |
| Pfizer INC. | $12.02 | 2021 | |
| Intercept Pharmaceuticals, INC. | $11.41 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$366,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Keller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.